

---

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-A**

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES  
PURSUANT TO SECTION 12(b) OR (g) OF THE  
SECURITIES EXCHANGE ACT OF 1934

**PROPANC BIOPHARMA, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State of incorporation  
or organization)

**33-0662986**

(I.R.S. Employer  
Identification No.)

**302, 6 Butler Street**  
**Camberwell, VIC, 3124 Australia**

(Address of principal executive offices)

**n/a**

(Zip Code)

Securities to be registered pursuant to Section 12(b) of the Act:

Title of each class to be so registered

**Common Stock, par value \$0.001 per share**

Name of each exchange on which each class is to be registered

**The Nasdaq Stock Market LLC**

If this Form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. ☒

If this Form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ☐

If this Form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐

Securities Act registration statement or Regulation A offering statement file number to which this form relates: **333-282886**

Securities to be registered pursuant to Section 12(g) of the Act: **None.**

---

---

**INFORMATION REQUIRED IN REGISTRATION STATEMENT**

**Item 1. Description of the Registrant's Securities to be Registered.**

A description of the common stock, par value \$0.001 per share (the "**Common Stock**"), of Propanc Biopharma, Inc., a Delaware corporation (the "**Registrant**"), is set forth under the heading "*Description of Our Securities*" contained in the Registrant's Registration Statement on Form S-1 (File No. 333-282886), originally filed with the Securities and Exchange Commission on October 30, 2024, as subsequently amended, and is hereby incorporated herein by reference. The description of the Common Stock included in any form of prospectus subsequently filed by the Registrant pursuant to Section 424(b) of the Securities Act of 1933, as amended, shall also be deemed to be incorporated herein by reference.

**Item 2. Exhibits.**

Pursuant to the "Instructions as to Exhibits" with respect to Form 8-A, no exhibits are required to be filed because no other securities of the Registrant are registered on the Nasdaq Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

---

**SIGNATURE**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

**Propanc Biopharma, Inc.**

Date: August 13, 2025

By: /s/ James Nathanielsz  
James Nathanielsz

Chief Executive Officer

---